Teleflex Strengthens Arrow®Pain Management Portfolio with Addition of theAutoFuser®Disposable Pain Pump
LIMERICK, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYS: TFX) announced today the addition of the AutoFuser® disposable pain pump to its portfolio of Arrow® pain management products. The AutoFuser pump is designed to provide an accurate and flexible method to deliver analgesic medication for continuous peripheral nerve block or site-specific applications, helping physicians to take control of patients' post-operative pain to promote faster recovery and reduce overall length of stay.
The addition of the AutoFuser pain pumps to the Teleflex® portfolio is a result of the company's recent acquisition of substantially all of the assets of LMA International N.V.
"The practice of regional anesthesia continues to grow at an impressive rate," said Cary Vance, President, Anesthesia and Respiratory Division. "The addition of AutoFuser pumps to our portfolio of pain management products, which includes the Arrow StimuCath® peripheral nerve block catheter, positions Teleflex to capitalize on this growth while meeting the needs of our core customer."
AutoFuser pain pumps are available in three different sizes with a selection of fixed or variable basal infusion rates, allowing physicians to customize their patients' pain protocol. The parallel bolus feature allows patients to administer a controlled amount of additional anesthetic to the target site without interrupting the continuous infusion of medication, providing an effective method to manage breakthrough pain, which is a common post-operative challenge. The pump is not manufactured with natural rubber latex, supporting many hospitals' material safety protocols.
This new disposable pain pump can be used in conjunction with the recently released Arrow® FlexBlock™ continuous peripheral nerve block catheter. The FlexBlock catheter features an echogenic, coil-reinforced design that offers a combination of ultrasound visibility, flexibility, and excellent kink resistance.
"These two new products further strengthen our presence in the field of pain management," said Vance. Teleflex's Arrow Pain Management portfolio includes peripheral nerve block catheters and needles, peripheral nerve stimulators, spinal anesthesia trays, and epidural catheters. Learn more at teleflex.com.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,100 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Arrow, StimuCath, FlexBlock, and Teleflex are trademarks or registered trademarks of Teleflex Incorporated. AutoFuser is a registered trademark of Ace Medical Co., Ltd.
©2013 Teleflex Incorporated. All rights reserved. 2013-1771.
Treasurer and Vice President, Investor Relations
KEYWORDS: United States North America Pennsylvania
The article Teleflex Strengthens Arrow® Pain Management Portfolio with Addition of the AutoFuser® Disposable Pain Pump originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.